Immunodeficiency Secondary to Malignancies and Biologics
Editor
Bernstein, Jonathan A.
Department
Allergy and Immunology
Document Type
Book Chapter
Publication Title
Primary and Secondary Immunodeficiency: A Case-Based Guide to Evaluation and Management
Abstract
There are many causes for secondary immunodeficiency (SID), which commonly presents with increased risk of infections. B-cell malignancies (multiple myeloma, chronic lymphocytic leukemia, non-Hodgkin’s lymphoma) and chemotherapeutics with B-cell depleting treatments such as rituximab are increasingly recognized risk factors for SID. This chapter discusses the diagnostic approach to patients with SID due to malignancy and biologics, including evaluation of immunoglobulin (Ig) levels and the importance of assessing a vaccine response. The chapter also discusses management options with prophylactic vaccination, prophylactic antibiotics, and Ig replacement (IgR), with a discussion on the pros and cons of intravenous versus subcutaneous administration of IgR.
DOI
10.1007/978-3-030-57157-3_21
Publication Date
2021
Recommended Citation
Mustafa, S. S. (2021). Immunodeficiency Secondary to Malignancies and Biologics. Primary and Secondary Immunodeficiency: A Case-Based Guide to Evaluation and Management https://doi.org/10.1007/978-3-030-57157-3_21